Who are Co-Diagnostics, Inc.'s major customers?

Co-Diagnostics, Inc. (CODX) key customers include: ONE-CUSTOMER, ONE-GRANTING-AGENCY, TWO-GRANTING-AGENCIES, Abbott Laboratories, Abbott Laboratories and 8 more. View the full customer network at chainsifter.com/chain/CODX.

What sector is Co-Diagnostics, Inc. in?

Co-Diagnostics, Inc. (CODX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Co-Diagnostics, Inc. (CODX) Supply Chain: 16 Verified Relationships

0Suppliers

13Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Co-Diagnostics, Inc. (CODX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

17Total relationships

3Distinct source URLs

7High confidence

0.747Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Co-Diagnostics, Inc. Suppliers

No suppliers on recordCo-Diagnostics, Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.

Co-Diagnostics, Inc. Customers

Ticker	Name	Confidence	Evidence
ONE-CUSTOMER	ONE-CUSTOMER	90%	One customer accounted for approximately 31 % of product revenue for the year ended December 31, 2024.
ONE-GRANTING-AGENCY	ONE-GRANTING-AGENCY	90%	One granting agency accounted for 100 % of grant revenue for the year ended December 31, 2025,
TWO-GRANTING-AGENCIES	TWO-GRANTING-AGENCIES	90%	two granting agencies accounted for approximately 95 % of grant revenue for the year ended December 31, 2024.
ABT	Abbott Laboratories	72%	Reciprocal relationship from ABT graph: Reciprocal relationship from CODX graph: Reciprocal relationship from ABT graph: Reciprocal relationship from CODX graph: Reciprocal relationship from ABT grap…
ABT	Abbott Laboratories	72%	tors already have an established customer base with industry standard technology, which we must overcome to be successful. In the diagnostic testing and POCT industries, we compete with such companie…
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	on with our customers, have designed tests that identify genetic traits in plant and animal genomes. We also have commercialized three multiplexed tests to test mosquitos for the presence of diseases…
CLEAR-STREET-LLC	CLEAR-STREET-LLC	62%	ities of $29.2 million for the year ended December 31, 2024. The slight decrease in cash used in operating activities was primarily due to lower operating expenses, primarily legal expenses, offset b…
COSARA-DIAGNOSTICS-PVT-LTD	COSARA-DIAGNOSTICS-PVT-LTD	62%	with our joint venture, CoSara) to sell PCR diagnostic tests for the detection of COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the Zik…
IDAHO-MOLECULAR-INC	IDAHO-MOLECULAR-INC	62%	on equity method investment in joint venture (46,301 ) (186,067 ) 139,766 -75 % Total other income, net 1,653,438 2,499,670 (846,232 ) -34 % Loss before income taxes (48,511,914 ) (37,581,640 ) (10,9…
MAXIM-GROUP-LLC	MAXIM-GROUP-LLC	62%	ities of $29.2 million for the year ended December 31, 2024. The slight decrease in cash used in operating activities was primarily due to lower operating expenses, primarily legal expenses, offset b…
SALTRIDGE-LLC	SALTRIDGE-LLC	62%	s with the SEC, overseeing all aspects of the company’s annual audit, including, but not limited to, the preparation and review of audit support schedules, preparation of financial statements and foo…
WAREHOUSE-HOLDINGS-INC	WAREHOUSE-HOLDINGS-INC	62%	s with the SEC, overseeing all aspects of the company’s annual audit, including, but not limited to, the preparation and review of audit support schedules, preparation of financial statements and foo…
WHITEKNOB-LLC-WHITEKNOB-LLC	WHITEKNOB-LLC-WHITEKNOB-LLC	62%	to acquire 682 shares of common stock. Equity Compensation Plan Information Plan Category (a) Number of Shares to be Issued upon Exercise of Outstanding Options and Rights (b) Weighted-average Exerci…

Co-Diagnostics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CODX-DEBT	Debt stack $3.8M	90%	Market cache reports total debt of $3.8M.
CODX-DEBT-8772	Warrants outstanding: 456000	90%	xbrl warrant detail from xbrl 2022-03-31.
CODX-DEBT-8773	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2019-12-31.

Co-Diagnostics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Co-Diagnostics, Inc..

Co-Diagnostics, Inc. Ownership

Holder	Name	Confidence	Evidence
CODX-OWNER-PRIVATE-ADVISORY-GROUP-LLC	Private Advisory Group LLC	90%	13F overlay lists Private Advisory Group LLC as top holder; 10 tracked holders.

Co-Diagnostics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
NBP	NovaBridge Biosciences	100.00	2
NSPR	InspireMD, Inc.	100.00	2
ITGR	Integer Holdings Corporation	100.00	2
IINN	Inspira Technologies Oxy B.H.N. Ltd.	100.00	2
NVS	Novartis AG	100.00	2
MTLS	Materialise NV	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
GRAL	GRAIL, Inc.	100.00	2
ALVO	Alvotech	100.00	2
GRFS	Grifols, S.A.	100.00	2
PSNL	Personalis, Inc.	100.00	2
FLGT	Fulgent Genetics, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
GIKLY	Grifols, S.A.	100.00	2
GCTK	GlucoTrack, Inc.	100.00	2
EXAS	Exact Sciences Corp	100.00	2
GIFOF	Grifols, S.A.	100.00	2
IVA	Inventiva S.A.	100.00	2
GIFLF	Grifols, S.A.	100.00	2
NVEC	NVE Corporation	100.00	2

Co-Diagnostics, Inc. Supply Chain